SCHEMBL7679172

SCHEMBL7679172

CS(=O)(=O)c1ccc(Sc2ccc(Cl)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.56
FAAH O00519 2/20 0.51
KCNH2 Q12809 2/20 0.51
PTGS1 P23219 2/20 0.50
ALDH1A1 P00352 2/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAOB P27338 1/20 0.47
RORC P51449 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA3 P07451 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265232 0.87 PTGS2 (0.69) PTGS2PTGS1ALDH1A1CYP3A4MAPK1
SCHEMBL8978672 0.83 ALDH1A1 (0.73) ALDH1A1CYP3A4MAPK1LMNAHPGD
SCHEMBL9476326 0.83 ALDH1A1 (0.73) ALDH1A1CYP3A4MAPK1LMNAHPGD
SCHEMBL13949922 0.81 PTGS2 (0.56) PTGS2PTGS1ALDH1A1CYP3A4L3MBTL1
SCHEMBL7210087 0.81 PTGS2 (0.53) PTGS2FAAHKCNH2PTGS1ALDH1A1
SCHEMBL5052857 0.80 PTGS2 (0.74) PTGS2PTGS1ALDH1A1CYP3A4MAPK1
Potassium Ion SCHEMBL11610857 0.79 ALDH1A1 (0.48) ALDH1A1CYP3A4MAPK1LMNAHPGD
SCHEMBL5806599 0.79 CA2 (0.75) PTGS2PTGS1ALDH1A1CYP3A4MAPK1
SCHEMBL1331687 0.78 MEN1 (0.56) PTGS2FAAHKCNH2ALDH1A1CYP3A4
SCHEMBL481976 0.76 MAOA (0.64) ALDH1A1CYP3A4MAPK1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 US disclosed
US-6294573-B1 FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION ABBOTT LABORATORIES 2001-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases MMP1, MMP9, MMP3 PTGS2 199/4885FAAH 952/4885KCNH2 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.